Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 10;11(1):37.
doi: 10.1186/s12348-021-00267-x.

Intraocular therapy in noninfectious uveitis

Rocco Luigi Modugno  1 , Ilaria Testi  2 , Carlos Pavesio  3   4
Affiliations
Review

Intraocular therapy in noninfectious uveitis

Rocco Luigi Modugno et al. J Ophthalmic Inflamm Infect. .

Abstract

Systemic corticosteroids and immunosuppressant agents are the mainstay of therapy for non-infectious uveitis (NIU). However, the risks associated with systemic administration and the need of delivering an effective and safe anti-inflammatory treatment targeted to the site of inflammation have prompt the use of local therapy in the management of NIU. This review will analyse the different local treatment options available, including corticosteroids, anti-vascular endothelial growth factor (VEGF), methotrexate and the recent biologics.

Keywords: Anti-tumor necrosis factor (TNF) α; Anti-vascular endothelial growth factor (VEGF); Biologics; Corticosteroids; Immunosuppressive agents; Intravitreal; Local therapy; Methotrexate; Non-infectious uveitis.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159–1162. doi: 10.1136/bjo.2003.037226. - DOI - PMC - PubMed
    1. de Smet MD, Taylor SRJ, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452–470. doi: 10.1016/j.preteyeres.2011.06.005. - DOI - PubMed
    1. Bansal P, Agarwal A, Gupta V, Singh R, Gupta A. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema. Indian J Ophthalmol. 2015;63(5):416–422. doi: 10.4103/0301-4738.159870. - DOI - PMC - PubMed
    1. Lehoang P. The gold standard of noninfectious uveitis: corticosteroids. Dev Ophthalmol. 2012;51:7–28. doi: 10.1159/000336676. - DOI - PubMed
    1. Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011;12(7):1127–1131. doi: 10.1517/14656566.2011.571209. - DOI - PubMed

LinkOut - more resources